Racial and Socioeconomic Disparities in Presentation and Outcomes of Well-Differentiated Thyroid Cancer
Open Access
- 1 January 2014
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (1), 133-141
- https://doi.org/10.1210/jc.2013-2781
Abstract
Context: Racial/ethnic minorities suffer disproportionate morbidity and mortality from chronic diseases. Objective: Our objective was to assess racial and socioeconomic status (SES) disparities in well-differentiated thyroid cancer (WDTC) patients. Design and Participants: We conducted a retrospective cohort study on 25 945 patients with WDTC (1999–2008) from the California Cancer Registry (57% white, 4% black, 24% Hispanic, and 15% Asian-Pacific Islander [API]). Main Outcomes: We evaluated effect of race and SES variables on stage of cancer presentation and overall/disease-specific survival. Results: Significant differences in stage of presentation between all racial groups were found (P < .001), with minority groups presenting with a higher percentage of metastatic disease as compared with white patients (black, odds ratio [OR] = 1.36 with confidence interval [CI] 1.01–1.84; Hispanic, OR = 1.89 [CI, 1.62–2.21], API, OR = 1.82 [CI, 1.54–2.15]). Hispanic (OR = 1.59, [CI, 1.48–1.72]) and API (OR = 1.32 [1.22–1.44]) patients also presented with higher odds of regional disease. Patients with the lowest SES presented with metastatic disease more often than those with the highest SES (OR = 1.45 [CI, 1.16–1.82]). Those that were poor/uninsured and/or with Medicaid insurance had higher odds of presenting with metastatic disease as compared with those with private insurance (OR = 2.41, [CI, 2.10–2.77]). Unadjusted overall survival rates were higher among API and Hispanic patients and lower among black patients (P < .001 vs white patients). Adjusted overall survival also showed a survival disadvantage for black patients (hazard ratio = 1.4, [CI, 1.10–1.73]) and survival advantage for API patients (hazard ratio = 0.83, [CI, 0.71–0.97]). In disease-specific survival analyses, when only those patients with metastatic disease were analyzed separately, black patients again had the lowest survival rates, and Hispanic/API patients had the highest survival rates (P < .04). Conclusion: Black patients and those with low SES have worse outcomes for thyroid cancer. API and Hispanic patients may have a protective effect on survival despite presenting with more advanced disease.Keywords
This publication has 34 references indexed in Scilit:
- Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United StatesGynecologic Oncology, 2013
- Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women’s Health InitiativeBreast Cancer Research and Treatment, 2013
- Health Disparities in Endocrine Disorders: Biological, Clinical, and Nonclinical Factors—An Endocrine Society Scientific StatementJournal of Clinical Endocrinology & Metabolism, 2012
- The State of Research on Racial/Ethnic Discrimination in The Receipt of Health CareAmerican Journal of Public Health, 2012
- Thyroid Cancer Incidence and Survival in the National Cancer Institute Surveillance, Epidemiology, and End Results Race/Ethnicity GroupsThyroid®, 2010
- Trends in thyroid cancer demographics and surgical therapy in the United StatesSurgery, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Exposure to indoor pesticides during pregnancy in a multiethnic, urban cohort.Environmental Health Perspectives, 2003
- Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries.American Journal of Public Health, 1996
- Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system.1992